yesterday Acadia announced the departure of Michael Yang who was the commercial director and vice president. he is said to have received the post of CEO from another biotech. the strange and curious thing is that he has joined in 2017 and acadia since he has made great progress. in its place a lady who entered in February 2018 and then fully followed the entry of trofinetide into Acadia and its development. I don't know what this news could lead to, but in fact it happens on the eve of a quarterly report scheduled for the end of February, where inevitably they will have to communicate expenses and progress obtained regarding the trofinetide trial and almost certainly the results of 2591 known per item of Neuren.questions: in which biotech does this gentleman who knows everything about trofinetide go? why such a significant change at the top of Acadia before a quarterly in which important elements will be communicated for the reading of the current state of trofinetide? why is Neuren, who finished 2591's studies in December last year, continuing to communicate data in February?he is convinced that over the next month we will have significant elements to understand where, how and to what extent our investment has evolved.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)